Literature DB >> 376773

Transfer of specific unresponsiveness to organ allografts by thymocytes. Specific unresponsiveness by thymocyte transfer.

W S Hendry, N L Tilney, W M Baldwin, M J Graves, E Milford, T B Strom, C B Carpenter.   

Abstract

Prolonged survival of vascularized organ allografts has been produced in unmodified inbred rats by transfer of thymocytes from enhanced, engrafted, syngeneic animals. For these thymocytes to increase significantly the survival of test allografts they must be harvested 6-9 d after transplantation. Thymectomy of the enhanced, engrafted animals during the same critical period causes acute rejection of othewise long surviving grafts. For optimal effect, the enhanced thymocyte donor must be actively and passively immunized and receive a cardiac allograft. The necessity for erythrocytes in the initial active immunization regimen is noted. Additionally, the antigenic specificity of the suppressor effect has been established with two histoincompatible donor rat strains. Cellular and humoral host responses mounted by test graft recipients after thymocyte transfer from enhanced, engrafted donors are different from those mounted either by unmodifed animals acutely rejecting their grafts or by enhanced rats bearing well-functioning grafts. Numbers of T lymphocytes are reduced in the grafted hearts and in the spleens of test graft recipients, a finding paralleled by the complete absence of specific direct lymphocyte-mediated cytotoxicity. In contrast, cytotoxic antibody production, although delayed, is increased in magnitude, peaking around the time of graft rejection. These studies provide evidence that different biological manipulations can modify separate pathways in the complex cellular and humoral responses towards organ allografts. They demonstrate that cellular immunity is critically involved in immunological enhancement of vascularized organ allografts, a phenomenon hitherto considered primarily humoral. It seems clear that cells with suppressor activity are present within the thymus during the early phases of immunological enhancement.

Entities:  

Mesh:

Year:  1979        PMID: 376773      PMCID: PMC2184878          DOI: 10.1084/jem.149.5.1042

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  33 in total

1.  Cellular and humoral immunity after allogeneic renal transplantation in the rat. V. Appearance of anti-idiotypic antibody and its relationship to cellular immunity after treatment with donor spleen cells and alloantibody.

Authors:  F P Stuart; D M Scollard; T J McKearn; F W Fitch
Journal:  Transplantation       Date:  1976-11       Impact factor: 4.939

2.  Immunological enhancement of tumor homografts in mice: a review.

Authors:  N KALISS
Journal:  Cancer Res       Date:  1958-10       Impact factor: 12.701

3.  Prolongation of organ allograft survival by syngeneic lymphoid cells.

Authors:  N L Tilney; M J Graves; T B Strom
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

4.  Absence of suppressor cells from rats bearing passively enhanced kidney allografts.

Authors:  J R Batchelor; L Brent; P J Kilshaw
Journal:  Nature       Date:  1977-12-08       Impact factor: 49.962

5.  Enhanced allograft survival by combined active and passive immunization. Requirement of both erythrocytes and leukocytes.

Authors:  W M Baldwin; W L Null; J Notis-McConarty; N L Tilney
Journal:  Transplantation       Date:  1978-03       Impact factor: 4.939

6.  Further studies on suppressor T cells in mice unresponsive to H-2-incompatible skin grafts.

Authors:  P J Kilshaw; L Brent
Journal:  Transplant Proc       Date:  1977-03       Impact factor: 1.066

7.  Identification, cytotoxicity, and suppressor activity of infiltrating cells from enhanced organ allografts.

Authors:  N L Tilney; T B Strom; D B Booth; A Finnegan; P Lundin; C B Carpenter
Journal:  Transplant Proc       Date:  1977-03       Impact factor: 1.066

8.  Suppressor T cells arising in mice undergoing a graft-vs-host response.

Authors:  K Pickel; M K Hoffmann
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

9.  Cellular components of allograft rejection: identity, specificity, and cytotoxic function of cells infiltrating acutely rejecting allografts.

Authors:  T B Strom; N L Tilney; J M Paradysz; J Bancewicz; C B Carpenter
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

10.  Recirculating, suppressor T cells in transplantation tolerance.

Authors:  S Dorsch; R Roser
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

View more
  7 in total

1.  Is transplantation tolerable?

Authors:  Terry B Strom
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

2.  2006 Homer W. Smith Lecture: taming T cells.

Authors:  Terry B Strom
Journal:  J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 10.121

Review 3.  The biology of acute transplant rejection.

Authors:  N L Tilney; J W Kupiec-Weglinski
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

4.  Atrophy of the thymic cortex in mice with granulomatous schistosomiasis mansoni.

Authors:  S R Wellhausen; D L Boros
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

5.  Mechanisms maintaining enhancement of allografts. I. Demonstration of a specific suppressor cell.

Authors:  B M Hall
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

6.  Specific suppression of allograft rejection by trinitrophenyl (TNP)-induced suppressor cells in recipients treated with TNP-haptenated donor alloantigens.

Authors:  I V Hutchinson; W H Barber; P J Morris
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

7.  Immunological properties of subcellular rat lymphocyte preparations. Primary allogeneic stimulation in vitro by fractions containing Ia (RT1-B), but not RT1-A antigens.

Authors:  A Kaldany; C B Carpenter; C A Shadur; K George; A P Lundin; M Suthanthiran; T B Strom
Journal:  J Exp Med       Date:  1980-04-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.